Aktis Oncology

AKTS13F as of Jun 30, 2026 · next update ~Nov 14

Limited coverage

Only 1 fund we track owns this stock, so quarterly sentiment and aggregates may be sparse.

Who's buying AKTS

Top funds mostly added to Aktis Oncology in Q2 (Apr⁠–⁠Jun)

Buying:

Funds1Insiders6Congress

Top funds
1 of 1 bought more, 0 sold some. Largest: Polen Capital Management, $2.0M (0% of its portfolio).
Insiders
6 insiders bought, 5 sales in 12 months.
Congress
No trades disclosed in the last 12 months.

1 fund$2.0M held0.0% avg. weightQ2: 1 bought / 0 sold

13F reports are a snapshot as of Jun 30, 2026; funds may have traded since. Insiders often sell for personal reasons (taxes, diversification, planned sales).

Share price · market data, not from 13F reports

Q2 2026

Insider trades (Form 4)

Last 2 years · 11 filings

Net buying$117.54M

Date	Insider	Type	Shares	Price	Value
Sep 23, 2026	Akos Czibere	Sold	12,500	$20.69	$259K
Jul 20, 2026	Ken Herrmann Director	Sold	4,856	$24.56	$119K
Jul 17, 2026	Ken Herrmann Director	Sold	3,065	$25.21	$77K
Jul 8, 2026	Shulamit Ron-bigger COO	Sold	50,000	$27.75	$1.39M
Jul 8, 2026	Akos Czibere	Sold	50,000	$27.77	$1.39M
Jan 12, 2026	Todd Foley Director & 10% Owner	Bought	232,870	$18.00	$4.19M
Jan 12, 2026	Mpm Bioventures 2018, L.P. 10% Owner	Bought	1,112,777	$18.00	$20.03M
Jan 12, 2026	Ansbert Gadicke 10% Owner	Bought	1,112,777	$18.00	$20.03M
Jan 12, 2026	Ecor1 Capital, LLC Director	Bought	2,222,222	$18.00	$40.00M
Jan 12, 2026	Vida Ventures Ii, LLC 10% Owner	Bought	835,000	$18.00	$15.03M
Jan 12, 2026	Helen Susan Kim Director & 10% Owner	Bought	835,000	$18.00	$15.03M